Maia biotechnology, inc. MAIA.US Overview
BetaUS StockHealthcare
(No presentation for MAIA)
MAIA AI Analysis & Strategy
Analysis Conclusion
With insufficient quarterly financial data released by the company, we're unable to provide a rating.
MAIA Current Performance
-2.63%
Maia biotechnology, inc.
0.98%
Avg of Sector
0.83%
S&P500
MAIA Key Information
MAIA Financial Forecast
Unit : USD
MAIA Earnings Table
No related data records
MAIA Profile
MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer, primarily non-small cell lung cancer. Its lead asset, THIO, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The company was founded in 2018 and is headquartered in Chicago, Illinois.